Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)

CAPS Rating: 4 out of 5

The Company is a clinical-stage drug development company that discovers and develops novel, small molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases.


Player Avatar zzlangerhans (99.85) Submitted: 11/17/2010 3:08:29 PM : Outperform Start Price: $7.73 RIGL Score: -65.97

Rigel is a company I always keep my eye on when the share price is low, because of the explosion in their share price that occurred in late 2007 with encouraging phase II data for their RA drug R788, now known as fostamatinib. Since then, the development of R788 has proceeded with a few hiccups such as noted side effects of hypertension and elevated liver enzymes, as well as a partnership deal with AstraZeneca that many perceived as being excessively backloaded. AstraZeneca is now on the cusp of initiating patient dosing in phase III trials of R788 but Rigel's share price has declined from recent highs of 8.7. I expect a rebound at some point in the near future once the trials are underway. If not, I'll re-establish this as a GBMB buy under 7.

Report this Post 2 Replies
Member Avatar trackjakeambrose (55.19) Submitted: 7/19/2012 7:09:10 PM
Recs: 0

your insights are very appreciated. id love to befriend you on a personal level to pick your brain once and a while. id never get bothersome. of course i understand if you dont.

Member Avatar zzlangerhans (99.85) Submitted: 4/5/2013 9:32:01 AM
Recs: 1

Bought 2000 shares at 4.91 for the Portefeuille collaboration.

Featured Broker Partners